Targeted Therapy Based on Molecular Profiling + Standard-of-Care Therapy
Phase 2Active 1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Malignant Neoplasm
Conditions
Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm
Trial Timeline
May 13, 2014 → Dec 31, 2030
NCT ID
NCT02152254About Targeted Therapy Based on Molecular Profiling + Standard-of-Care Therapy
Targeted Therapy Based on Molecular Profiling + Standard-of-Care Therapy is a phase 2 stage product being developed by Tempus AI for Metastatic Malignant Neoplasm. The current trial status is active. This product is registered under clinical trial identifier NCT02152254. Target conditions include Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Malignant Neoplasm were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
12
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02152254 | Phase 2 | Active |
Competing Products
20 competing products in Metastatic Malignant Neoplasm